Want to see VKTX full AI Analyst Report?

Viking Therapeutics (VKTX) Price & Analysis

7,519 Followers

VKTX Stock Chart & Stats

$35.20

$0.22(0.67%)

At close: Jan 21 4:00 PM EST

$35.20

$0.22(0.67%)

Day’s Range― - ―

52-Week Range$22.96 - $43.15

Previous CloseN/A

Volume7.75M

Average Volume (3M)2.64M

Market Cap

$4.51B

Enterprise Value$3.40B

Total Cash (Recent Filing)$602.96M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.21

Next Earnings

Jul 29, 2026

EPS Estimate

-1.23

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.14

Shares Outstanding116,105,644

10 Day Avg. Volume2,526,007

30 Day Avg. Volume2,637,810

Financial Highlights & Ratios

PEG Ratio-0.05

Price to Book (P/B)6.20

Price to Sales (P/S)0.00

P/FCF Ratio-14.22

Enterprise Value/Market Cap0.75

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-16.34K

Enterprise Value/Ebitda-7.20

Forecast

1Y Price Target

$92.91

Price Target Upside163.95% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)-4.75

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageNear-zero debt materially reduces refinancing and interest-rate risk for a clinical-stage biotech. This conservative capital structure preserves strategic optionality to fund trials, pursue partnerships, or withstand development delays without immediate debt pressure.

Substantial Equity BaseA meaningful equity balance (~$501.9M TTM) provides a multi-month funding cushion to continue R&D and clinical programs, enabling milestone-driven progress and potential partnering discussions before urgent capital raises become necessary.

Focused PipelineConcentrated R&D focus on metabolic and endocrine disorders, including the VK2735 GLP‑1/GIP program, aligns resources on a clear therapeutic area. This specialization can improve trial design efficiency, deepen expertise, and make the company an attractive partner for collaborators.

Bears Say

Pre-revenue & Large LossesBeing pre-revenue with materially widening net losses (-$472.3M TTM) means the company depends entirely on external financing or partnerships to survive. Persistent losses increase dilution risk and make long-term sustainability contingent on successful clinical results.

Accelerating Cash BurnOperating cash flow deteriorated to -$340.3M TTM (from -$47.6M in 2021), reflecting rising R&D and trial spending. Accelerating negative cash flow shortens runway, pressures management to raise capital more frequently, and increases execution and dilution risk over months.

Declining Equity CushionEquity has declined sharply (from $880.3M to $501.9M TTM), indicating repeated financing and/or accumulated losses. A shrinking equity base reduces the balance-sheet cushion, making future capital raises more dilutive and raising the likelihood of financing-related execution risks.

Viking Therapeutics News

Viking Therapeutics call volume above normal and directionally bullish

Bullish option flow detected in Viking Therapeutics (VKTX) with 9,977 calls trading, 3x expected, and implied vol increasing...

19d ago

VKTX

Viking catalysts include VK3019, VK2735 readouts in Q3, says Raymond James

Raymond James tells investors in a research note that Viking Therapeutics (VKTX) initiated a Phase 1 single ascending...

20d ago

VKTX

Viking Therapeutics begins Phase 1 SAD clinical trial of VK3019

Viking Therapeutics (VKTX) announced the initiation of a Phase 1 single ascending dose, or SAD, clinical trial of...

20d ago

VKTX

Viking Therapeutics call volume above normal and directionally bullish

Bullish option flow detected in Viking Therapeutics (VKTX) with 8,418 calls trading, 1.3x expected, and implied vol increasing...

26d ago

VKTX

Viking Therapeutics management to meet with B. Riley

Meeting to be held in Denver on June 22 hosted by B. Riley. Published first on TheFly –...

29d ago

VKTX

Viking Therapeutics: Advancing Obesity Pipeline Supports Buy Rating and Unchanged $102 Price Target

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics today and set a price target...

20d ago

VKTX

Viking Therapeutics names Hubert Chen, M.D., as Chief Medical Officer

Viking Therapeutics (VKTX) announced the appointment of Hubert Chen, M.D., as chief medical officer. Dr. Chen brings more...

1M ago

VKTX

Analyst Reiterates Buy on Viking Therapeutics, Citing Best-in-Class Obesity Pipeline and Multiple Value-Creation Catalysts

William Blair analyst Andy Hsieh has reiterated their bullish stance on VKTX stock, giving a Buy rating on...

1M ago

VKTX

Dick’s Sporting upgraded, Trade Desk initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

Viking Therapeutics initiated with a Buy at Lake Street

Lake Street initiated coverage of Viking Therapeutics (VKTX) with a Buy rating and $89 price target based on...

2M ago

VKTX

Viking Therapeutics assumed with a Buy at Truist

Truist assumed coverage of Viking Therapeutics (VKTX) with a Buy rating with a price target of $83, up...

2M ago

VKTX

Viking Therapeutics Shareholders Back Board, Pay, and Auditor

Viking Therapeutics ( ($VKTX) ) has issued an update. On May 19, 2026, Viking Therapeutics held its 2026...

2M ago

VKTX

Viking Therapeutics’ VK2735 demonstrates wieght loss in Phase 2 trial

Viking Therapeutics (VKTX) presented additional data from its Phase 2 VENTURE-Oral Dosing trial evaluating the oral tablet formulation...

2M ago

VKTX

Nash Maintains Buy on Viking Therapeutics, Keeps $107 Price Target Unchanged Amid Strong Cash Runway and Expanded VK2735 Study

Viking Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst on May 1. Analyst Edward...

2M ago

VKTX

VKTX FAQ

What was Viking Therapeutics’s price range in the past 12 months?

Viking Therapeutics lowest stock price was $22.96 and its highest was $43.15 in the past 12 months.

What is Viking Therapeutics’s market cap?

Viking Therapeutics’s market cap is $4.51B.

When is Viking Therapeutics’s upcoming earnings report date?

Viking Therapeutics’s upcoming earnings report date is Jul 29, 2026 which is in 15 days.

How were Viking Therapeutics’s earnings last quarter?

Viking Therapeutics released its earnings results on Apr 29, 2026. The company reported -$1.37 earnings per share for the quarter, missing the consensus estimate of -$0.976 by -$0.394.

Is Viking Therapeutics overvalued?

According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Viking Therapeutics pay dividends?

Viking Therapeutics does not currently pay dividends.

What is Viking Therapeutics’s EPS estimate?

Viking Therapeutics’s EPS estimate is -1.23.

How many shares outstanding does Viking Therapeutics have?

Viking Therapeutics has 116,105,644 shares outstanding.

What happened to Viking Therapeutics’s price movement after its last earnings report?

Viking Therapeutics reported an EPS of -$1.37 in its last earnings report, missing expectations of -$0.976. Following the earnings report the stock price went down -0.479%.

Which hedge fund is a major shareholder of Viking Therapeutics?

Currently, no hedge funds are holding shares in VKTX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Viking Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-71.31%

Trailing 12-Months

Asset Growth

-29.84%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Viking Therapeutics

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

Viking Therapeutics (VKTX) Earnings & Revenues

Historic Earnings Reports

VKTX Stock 12 Month Forecast

Average Price Target

$92.91

▲(163.95% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","126":"$126","50.25":"$50.3","75.5":"$75.5","100.75":"$100.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":92.9090909090909,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$92.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$70.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,50.25,75.5,100.75,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.48,44.21230769230769,50.94461538461538,57.676923076923075,64.40923076923077,71.14153846153846,77.87384615384616,84.60615384615386,91.33846153846154,98.07076923076923,104.80307692307693,111.53538461538463,118.26769230769233,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.48,41.74377622377622,46.00755244755244,50.27132867132867,54.535104895104894,58.79888111888112,63.062657342657346,67.32643356643356,71.5902097902098,75.85398601398602,80.11776223776224,84.38153846153847,88.64531468531469,{"y":92.9090909090909,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.48,39.981538461538456,42.48307692307692,44.98461538461538,47.48615384615384,49.987692307692306,52.489230769230765,54.99076923076923,57.49230769230769,59.99384615384615,62.495384615384616,64.99692307692308,67.49846153846154,{"y":70,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.67,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.68,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.37,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.55,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.18,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.92,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.34,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.96,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.27,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.48,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >